23:41 , Apr 26, 2018 |  BC Innovations  |  Product R&D

Brake for gas

Elpiscience Biopharmaceuticals Co. Ltd. has emerged from stealth mode with an unconventional bispecific that simultaneously removes the brakes and steps on the gas for antitumor immunity, but only inside tumors. The goal is to upstage...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Company News

Active Biotech, NeoTX Therapeutics deal

Active granted NeoTX exclusive, worldwide rights to develop and commercialize Anyara naptumomab estafenatox for cancer. Active will receive a $250,000 upfront payment and is eligible for development, regulatory and commercialization milestones, plus double-digit royalties. Active...
07:00 , Sep 29, 2014 |  BioCentury  |  Finance

CureVac bet paying off

Although the Hopp family's biotech investments have posted mixed results in recent years, the €80 million marker Hopp put down in 2012 on CureVac GmbH seems to be paying off. The cancer vaccine and infectious...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

CureVac, Boehringer Ingelheim deal

CureVac granted Boehringer exclusive, worldwide rights to develop and commercialize CureVac's CV9202 . The vaccine is in a Phase Ib trial to treat metastatic non-small cell lung cancer (NSCLC). The deal includes a EUR35 million...
02:44 , Sep 19, 2014 |  BC Extra  |  Company News

Boehringer licenses CureVac's CV9202

Boehringer Ingelheim GmbH (Ingelheim, Germany) licensed exclusive, worldwide rights to develop and commercialize CV9202 from CureVac GmbH (Tuebingen, Germany). The candidate is in a Phase Ib trial to treat metastatic non-small cell lung cancer (NSCLC)....
07:00 , May 12, 2014 |  BioCentury  |  Finance

Vivid imaging

Vivid imaging Investors in ImaginAb Inc. 's $21 million series B round expect its lead agent will provide greater specificity and sensitivity in prostate cancer detection than CT or bone scans - and do so...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Company News

DanDrit Biotech USA, Oxford BioMedica, myTomorrows cancer news

Online patient platform myTomorrows will offer patients access to DanDrit's MelCancerVac and to an undisclosed therapeutic cancer vaccine from Oxford BioMedica. MelCancerVac is a dendritic cell-based vaccine that has completed Phase II testing to treat...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

PF-06263507: Phase I started

Pfizer began a 2-part, open-label, dose-escalation, U.S. Phase I trial to evaluate IV PF-06263507 in 21-day cycles in about 75 patients with advanced solid tumors. The first part will determine the maximum tolerated dose, with...
07:00 , May 27, 2013 |  BC Week In Review  |  Clinical News

Anyara naptumomab estafenatox: Additional Phase II/III data

In a subgroup analysis of the 25% of patients with low or normal levels of baseline IL-6 and expected anti-superantigen antibody levels, Anyara plus IFN alpha led to a median OS of 63.3 months vs....
07:00 , Apr 29, 2013 |  BioCentury  |  Strategy

Zerhouni's progress report

When Elias Zerhouni joined Sanofi as the head of R&D in January 2011, the former NIH director decided the pharma's pipeline needed to be pruned and refocused around disease pathways. Two years into the job,...